Veradermics, Inc (MANE) reported that Chief R&D Officer David Hollander received equity awards on September 1, 2026. He was granted 9,650 shares of Common Stock in the form of restricted stock units and a stock option for 19,300 shares at an exercise price of $97.51 per share, both held directly.
The RSUs vest 25% on each of September 1, 2027, 2028, 2029, and 2030, subject to continued service. The option vests 25% on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months and expires on September 1, 2036.
Veradermics, Inc. (MANE) received an updated Schedule 13D/A from investment entities associated with Montanova Capital, LLC and Aaron Cowen, detailing their current beneficial ownership and recent trades. Montanova Capital and Mr. Cowen report beneficial ownership of 3,718,970 shares of common stock, representing 8.8% of the outstanding shares, through Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.
On August 19, 2026, Averill Master Fund sold 690,601 shares and Averill Madison Master Fund sold 59,399 shares in open-market transactions at $107.25 per share. On August 20, 2026, Averill Master Fund exercised Pre-Funded Warrants for 149,000 shares and Averill Madison Master Fund exercised Pre-Funded Warrants for 151,000 shares at $0.00001 per share, funded from the Funds’ working capital.
Veradermics, Inc (MANE) had multiple entities associated with the reporting group, including Montanova Capital, LLC and Averill funds, report transactions in its securities. On 2026-08-20 they exercised 300,000 Pre-Funded Warrants into 300,000 shares of common stock, all reported as indirect ownership. On 2026-08-19 they reported indirect open-market or private sales of an aggregate 750,000 shares of common stock at a reported price of $107.25 per share. Resulting ownership balances are not provided in the data shown.
Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer. The filing reports no transactions and no beneficial ownership positions in Veradermics securities as of the reporting date.
Veradermics, Inc. (MANE) is the issuer of common stock that Averill Master Fund, Ltd., an affiliate, has filed to sell under Rule 144. The notice covers up to 690,601 shares of common stock, to be sold through BofA Securities, Inc. as broker on the NYSE. The shares were acquired from Veradermics upon conversion of Series B Preferred Stock, which was obtained on November 25, 2024 and converted on February 5, 2026. No other Rule 144 sales by this seller are listed for the prior three months.
Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.
Veradermics, Inc (MANE) reported insider activity by Chief Executive Officer Reid Alexander Waldman. On 2026-08-17 he exercised 3,452 stock options to acquire an equal number of common shares at an exercise price of $12.19 per share from a fully vested option. On the same date, he reported open-market sales totaling 67,500 common shares in multiple tranches at reported weighted-average prices between $106.07 and $111.28 per share, executed pursuant to a Rule 10b5-1 trading plan.
MANE has a planned resale of restricted securities under Form 144. The filing lists up to 87,000 shares of common stock to be sold through J.P. Morgan Securities LLC on the NYSE, with a proposed sale date of August 17, 2026.
The 87,000 shares are composed of 3,452 shares associated with stock options originally dated March 24, 2020, and 83,548 founder shares from the same date. These are sales by an existing holder, not a new issuance by the company.
MANE has filed a notice of proposed sale of 135,000 shares of common stock under Form 144. The filing lists an aggregate market value of $15,022,800 for these shares and shows 41,780,136 shares outstanding as of 08/17/2026 on the NYSE.
The 135,000 shares consist of 3,452 shares acquired through a stock option and 131,548 founder shares, both originally acquired from the issuer. No sales of these securities are reported during the past three months.